Brought to you by 
NuBiyota teams up with Takeda in new GI microbiome deal
Apr 2017
Executive Summary
Takeda Pharmaceutical Co. Ltd. signed its second microbiome deal in less than a week, this time partnering with NuBiyota LLC to discover and develop new therapies for undisclosed gastroenterology conditions.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Includes Royalty or Profit Split Information
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NuBiyota teams up with Takeda in new GI microbiome deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice